UBS Group’s Acadia Pharmaceuticals ACAD Stock Holding History

UBS Group’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-9,000	Closed	-$210K	–	10163
2021 Q4	$210K	Hold	9,000	–	–	﹤0.01%	5641
2021 Q3	$149K	Hold	9,000	–	–	﹤0.01%	5541
2021 Q2	$220K	Hold	9,000	–	–	﹤0.01%	5270
2021 Q1	$232K	Buy	+9,000	New	+$396K	﹤0.01%	5377
2018 Q1	–	Sell	-1,600	Closed	-$48K	–	7764
2017 Q4	$48K	Buy	+1,600	New	+$51.2K	﹤0.01%	5863
2015 Q2	–	Sell	-100	Closed	-$3K	–	8445
2015 Q1	$3K	Sell	100 -1,000	-91%	-$34.4K	﹤0.01%	8308
2014 Q4	$35K	Buy	+1,100	New	+$31.2K	﹤0.01%	6925

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

UBS Group's ACAD Position: Q1 2026 in Review

UBS Group reduced its Acadia Pharmaceuticals (ACAD) stake by 42% in Q1 2026, selling an estimated $7.67M and leaving 448,549 shares worth $9.98M. The position accounts for ﹤0.01% of the portfolio, ranked #3356.

UBS Group first reported a position in ACAD in Q4 2014 and has held it in 46 quarters since. The position peaked at $22.8M in Q4 2024. 341 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

UBS Group held 448,549 shares of Acadia Pharmaceuticals worth $9.98M as of Q1 2026.
UBS Group sold 320,843 Acadia Pharmaceuticals shares in Q1 2026, an estimated $7.67M.
Acadia Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #3356 holding.
UBS Group first reported a position in Acadia Pharmaceuticals in Q4 2014 and has held it in 46 quarters since.
UBS Group's Acadia Pharmaceuticals position peaked at $22.8M in Q4 2024.
341 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.